Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase II Randomized Study of Adjuvant Versus NeoAdjuvant Pembrolizumab (MK-3475) for Clinically Detectable Stage III-IV High-Risk Melanoma
Brief Summary: This phase II trial studies how pembrolizumab works before and after surgery in treating patients with stage III-IV high-risk melanoma. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving pembrolizumab before and after surgery may work better compared to after surgery alone in treating melanoma.


Options:
A: Arm Label: Arm I (adjuvant pembrolizumab); Type: EXPERIMENTAL; Interventions: Procedure: Biospecimen Collection, Procedure: Computed Tomography, Procedure: Magnetic Resonance Imaging, Biological: Pembrolizumab, Procedure: Therapeutic Conventional Surgery | Arm Label: Arm II (adjuvant and neoadjuvant pembrolizumab); Type: ACTIVE_COMPARATOR; Interventions: Procedure: Biospecimen Collection, Procedure: Computed Tomography, Procedure: Magnetic Resonance Imaging, Biological: Pembrolizumab, Procedure: Therapeutic Conventional Surgery | Intervention Type: PROCEDURE; Name: Biospecimen Collection; Assigned to Arm(s): Arm I (adjuvant pembrolizumab), Arm II (adjuvant and neoadjuvant pembrolizumab) | Intervention Type: PROCEDURE; Name: Computed Tomography; Assigned to Arm(s): Arm I (adjuvant pembrolizumab), Arm II (adjuvant and neoadjuvant pembrolizumab) | Intervention Type: PROCEDURE; Name: Magnetic Resonance Imaging; Assigned to Arm(s): Arm I (adjuvant pembrolizumab), Arm II (adjuvant and neoadjuvant pembrolizumab) | Intervention Type: BIOLOGICAL; Name: Pembrolizumab; Assigned to Arm(s): Arm I (adjuvant pembrolizumab), Arm II (adjuvant and neoadjuvant pembrolizumab) | Intervention Type: PROCEDURE; Name: Therapeutic Conventional Surgery; Assigned to Arm(s): Arm I (adjuvant pembrolizumab), Arm II (adjuvant and neoadjuvant pembrolizumab)
B: Arm Label: Dostarlimab (TSR-042) (singly); Type: EXPERIMENTAL; Interventions: Drug: Dostarlimab (TSR-042) (singly) | Arm Label: Dostarlimab (TSR-042) and Cobolimab TSR-022 (combination); Type: EXPERIMENTAL; Interventions: Drug: Dostarlimab (TSR-042) and TSR-022 (combination) | Intervention Type: DRUG; Name: Dostarlimab (TSR-042) (singly); Assigned to Arm(s): Dostarlimab (TSR-042) (singly) | Intervention Type: DRUG; Name: Dostarlimab (TSR-042) and TSR-022 (combination); Assigned to Arm(s): Dostarlimab (TSR-042) and Cobolimab TSR-022 (combination)
C: Arm Label: Placebo + Vemurafenib; Type: ACTIVE_COMPARATOR; Interventions: Drug: Placebo, Drug: Vemurafenib | Arm Label: Cobimetinib + Vemurafenib; Type: EXPERIMENTAL; Interventions: Drug: Vemurafenib, Drug: Cobimetinib | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo + Vemurafenib | Intervention Type: DRUG; Name: Vemurafenib; Assigned to Arm(s): Cobimetinib + Vemurafenib, Placebo + Vemurafenib | Intervention Type: DRUG; Name: Cobimetinib; Assigned to Arm(s): Cobimetinib + Vemurafenib
D: Arm Label: Dabrafenib plus Trametinib; Type: EXPERIMENTAL; Interventions: Drug: Dabrafenib, Drug: Trametinib | Arm Label: Vemurafenib; Type: ACTIVE_COMPARATOR; Interventions: Drug: Vemurafenib | Intervention Type: DRUG; Name: Dabrafenib; Assigned to Arm(s): Dabrafenib plus Trametinib | Intervention Type: DRUG; Name: Vemurafenib; Assigned to Arm(s): Vemurafenib | Intervention Type: DRUG; Name: Trametinib; Assigned to Arm(s): Dabrafenib plus Trametinib

Answer: A